Member Info for stephen11

@@@@Does the Chairman’s Statement elude to a Potential 2026–2027 Trade Sale?@@@

This is what has me wondering?

- He explicitly references TWO prior companies he led that were sold

- Axis Shield; acquired for £235m

- Horizon Discovery; acquired for £296m

Going by previous experience, a chairman never cites his previous sale exits in an RNS unless:

- He wants investors to view trade sale as a credible route

- He is subtly framing the idea as acceptable or logical

- He is broadcasting to potential buyers: “I’ve done it before, I can do it again”

- This is classic soft signalling

I have previously been dubious about the possibility of a buyout/trade sale although the evidence above might suggest otherwise.

GLA.

Stephen11.

What’s with the skiing ref and who is Tim?

I would hope there will be a significant rerate of the SP today 🙂

Pied Piper - without consulting AI, and just from your own knowledge - do you think a protracted legal battle would be good for any of the parties: EME, Conrad, and Nations. Genuine question?

For clarity about cash runway it would be good to get the DN loan confirmed before the meeting next Monday.

##Top 5 Advantages##

1. Strong clinical validation from NHS-backed pilot. The RNS confirms that NHS England’s own pilot data shows clear superiority of Genedrive’s rapid CYP2C19 testing, reinforcing that the product works, is scalable, and improves outcomes.

2. Real-world efficiency gains (bed days + staff hours saved).The RNS quantifies system-level savings: 62,500 bed days + 235,000 clinician hours saved annually. This directly appeals to the NHS’s biggest priority: efficiency and cost reduction.

3. Demonstrated clinical impact at point of care. 100% of patients in the rapid testing arm received results in time to influence prescribing, compared with only 12% in the lab arm. This positions Genedrive as necessary, not just “nice to have.”

4. Increased patient coverage and ethnic inclusivity. 33% non-responders identified vs 29% in lab testing. This shows Genedrive detects more at-risk patients, especially across diverse populations — a meaningful competitive advantage.

5. Alignment with NHS 10-year plan and national adoption goals. The language strongly signals that CYP2C19 testing is heading for system-wide rollout.

Genedrive is positioned as the preferred rapid platform (consistent with NICE wording).

##Top 5 Disadvantages##

1. No explicit commitment to procurement volumes. The RNS is positive but still does not say: “X Trusts will purchase the device now.” The market wants commercial orders — this is still missing.

2. Funding responsibility still sits with Trusts/ICBs. Rapid testing is not centrally funded, unlike lab testing (which could be reimbursed nationally). This may slow the pace of adoption, as Trusts must find local budgets.

3. Language is supportive but not operational. The RNS is full of validation and guidance — but no timetable, no contracts, and no revenues. This creates uncertainty around near-term cash flows.

4. Potential delays due to the ICB procurement cycle. Even with strong clinical data, ICB processes are often slow and bureaucratic, introducing timing risk (months, not weeks).

5. Raises market expectations without providing commercial closure

GLA.

Stephen11.

Ps...RNS communication from the company has greatly improved overall - in fairness.

Agree as below - Conrad have been very badly advised throughout.

1. Scotland MT-RNR1 Roll-out Progress Updates

The RNS said rollout begins now and covers all Scottish Health Boards “over the coming months”.

Expected news:

- Additional hospitals go live

- Volume of tests performed

- Early patient outcome data

- Quotes from clinicians / adoption metrics

- Why likely: Rollout already approved + funded (£800k).

2. CYP2C19 – Further NHS Implementation Pilot Starts

Now that the implementation guide is published, trusts are expected to begin pathway planning.

Expected news:

- A trust begins a CYP2C19 rapid genotyping pilot

- Hyperacute stroke units trialling Genedrive

- First post-guide procurement inquiries

Why likely: NHS guide essentially invites trusts to act.

3. Middle East Distributor / Sales Progress Updates

GDR has already:

- CE-IVD certification

- Mentioned expected early sales in Q1 FY26

- Q1 FY26 = July–September 2025 (we are inside this period).

Expected news:

- First purchase order from a hospital or Ministry of Health

- Pilot utilisation

Why likely: The company has signposted it clearly.

4. Cash runway / Loan update from David Nugent

- Loan negotiations ongoing, and the company has been very transparent.

Possible updates:

- Loan terms finalised

- Drawdown of funds

- Impact on runway

Why likely: They already announced willingness to do a loan.

5. NICE EVA – Real-World Evidence Completion for MT-RNR1

- This is ongoing and fully funded.

Expected news:

- Completion notice

- Submission confirmation

- Early data readout

- Impact: Moderate (unlocks broader NHS England adoption).

Why likely: Program is progressing as scheduled.

All to play for!

Thanks - I”ve signed up - doesn’t make it obvious how to post? Different format than here.

Is this an Australian sharechat similar to this.

If so, could someone post details on how/where to join - I’d love to give them a few home truths.

Ps - I too found myself reading that reply in an Australian accent 😂.

The difference is we now have a much higher amount of shares in circulation than 2-years ago because of dilutive fundraises.

The RNS confirms that the NHS is preparing the system for CYP2C19 rapid genotyping, clearly validating Genedrive’s platform, but leaves actual procurement timing and revenue impact still open.

Really good - but lacks financial timelines.

Slap it up you Conrad - you reap what you sow in life.

###Well done GDR###

Here’s why:

- “National roll-out” means ongoing, system-wide procurement, not pilots.

- Scotland is fully implemented before England — important political leverage.

- Hospitals aren’t buying “one or two units” — they’re integrating it as standard of care.

- The scale: Scotland has 15 neonatal units, all will adopt it.

- That implies recurring test usage per baby needing antibiotics.

- This is true commercialisation — not testing, not evaluation, not pilots.

GLA.

Stephen11.

How much were Conrad down?

Will want @

A deal with tag along rights by XX date or this will go to court.

Nations will clean title and not the possibility of protracted legal wrangling.

Not a massive uplift, though it looks like the market is beginning to factor in a successful £1m loan deal.

I also wouldn’t be surprised if we hear from the Saudi’s again. Once they decide on something in principle they don’t mess about.

Ex igne resurgam

1/ Salamander Energy - Ophir Energy (Thailand/Indonesia). After the main sale was completed, Ophir later bought out the remaining small 5–10% partners at a higher per-boe valuation than the original farmdown. This happened because the buyer needed full control for development and was willing to pay a 15–30% premium to remove minority complications.

2/ Premier Oil - Catcher Field (UK North Sea). Premier acquired the majority interest first, and later purchased EnCore’s minor 15% stake at a significant premium to earlier valuations. The uplift occurred because EnCore’s stake became the “final piece,” giving them leverage once the operator was already committed to sanctioning the project.

3/ Total/CNOOC - Uganda Lake Albert (Heritage/Tullow). After the main stake transfers were agreed, the remaining small minority positions were bought at higher valuations per barrel in order to streamline approvals before FID. This premium arose because Uganda required clarity on ownership, making the small partners’ stakes strategically valuable.

4/ PNG LNG (Exxon-led). Multiple partners with sub-10% interests were later bought out at 20–50% higher implied valuations once major buyers had already committed capital. Operators paid more because consolidating residual stakes reduced project risk and simplified financing.

5/ Woodside → WA/NT Basins (Mitsui/Mitsubishi follow-ons). Woodside sold major positions to Mitsui/Mitsubishi, who subsequently bought out smaller 5–10% partners at higher prices than the main farmdown. The premium was due to the buyers wanting clean ownership structures before development and financing, increasing the value of the remaining minority stakes.

GLA.

Stephen11.